Novartis acquires Kate Therapeutics to advance gene therapies

Novartis has announced the acquisition of Kate Therapeutics to enhance its portfolio of gene therapies for inherited neuromuscular diseases.

Related Posts

STAT+: 3 CRISPR advances to watch in 2024

Dec 27, 2023

Sage lays off 55% of R&D workforce and refocuses pipeline

Oct 18, 2024

Lilly touts Omvoh’s superiority over J&J’s Stelara in C...

Oct 16, 2024